Teva posts Phase 3 post hoc data on olanzapine LAI
Teva reported post hoc analyses from the Phase 3 SOLARIS trial on once-monthly subcutaneous olanzapine LAI TEV-749, including stabilization and low relapse rates, and data supporting direct switching from oral or short-acting olanzapine. FDA Prescription Drug User Fee Act (PDUFA) is expected in Q4 2026.